Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: Results from the SILVHIA study

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 6, 2013, Pages 559-566

  Jekell, Andreas ^a   Malmqvist, Karin ^a   Wallén, N Håkan ^a   Mörtsell, David ^a,b   Kahan, Thomas ^a  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Atenolol; Hypertension; Inflammation; Irbesartan; Left ventricular hypertrophy; Renin angiotensin system; Vascular function

Indexed keywords

ATENOLOL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRBESARTAN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENDOTHELIUM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEART STROKE VOLUME; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULSE PRESSURE; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ARTERIES; ATENOLOL; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; TETRAZOLES; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 84890555711     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000017     Document Type: Article

References (49)

1. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001; 38: 581-587.
2. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001; 104: 191-196.
3. Chae CU, Lee RT, Rifai N, et al. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38: 399-403.
4. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998;16: 1031-1041.
5. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl. 1998;16:S23-S29.
6. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57: 132-140.
7. Schiffrin EL. The immune system: role in hypertension. Can J Cardiol. 2013;29: 543-548.
8. González A, López B, Querejeta R, et al. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol. 2002;34: 1585-1593.
9. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170: 191-203.
10. Mazzolai L, Duchosal MA, Korber M, et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension. 2004;44: 277-282.
11. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur Heart J. 2012;33: 2088-2097.
12. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20: 71-78.
13. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001; 19: 1167-1176.
14. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102: 1388-1393.
15. Müller-Brunotte R, Edner M, Malmqvist K, et al. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens. 2005;23: 633-640.
16. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19: 303-309.
17. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369: 2079-2087.
18. Resnick LM, Catanzaro D, Sealey JE, et al. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. Am J Hypertens. 2004;17: 203-208.
19. Navalkar S, Parthasarathy S, Santanam N, et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 2001;37: 440-444.
20. Hlubocká Z, Umnerová V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens. 2002;16: 557-562.
21. Nyström F, Malmqvist K, Lind L, et al. Nurse-recorded clinic and ambulatory blood pressures correlate equally well with left ventricular mass and carotid intima-media thickness. J Intern Med. 2005;257: 514-522.
22. Li Y, Wang JG, Dolan E, et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension. 2006;47: 359-364.
23. Kappelgaard AM, Nielsen MD, Giese J. Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta. 1976;67: 299-306.
24. Fyhrquist F, Soveri P, Puutula L, et al. Radioimmunoassay of plasma renin activity. Clin Chem. 1976;22: 250-256.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-419.
26. Malmqvist K, Kahan T, Edner M, et al. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. J Hum Hypertens. 2007;21: 956-965.
27. Salles GF, Fiszman R, Cardoso CR, et al. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50: 723-728.
28. Masiha S, Sundström J, Lind L. Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. J Hum Hypertens. 2013;27: 13-17.
29. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46: 1118-1122.
30. Chen CH, Ting CT, Lin SJ, et al. Which arterial and cardiac parameters best predict left ventricular mass? Circulation. 1998;98: 422-428.
31. Roman MJ, Ganau A, Saba PS, et al. Impact of arterial stiffening on left ventricular structure. Hypertension. 2000;36: 489-494.
32. Cernes R, Peer M, Boaz M, et al. Relation of arterial properties to left ventricular hypertrophy in hypertensive adults: focus on gender-related differences. Angiology. 2010;61: 510-515.
33. Boutouyrie P, Laurent S, Girerd X, et al. Common carotid artery stiffness and patterns of left ventricular hypertrophy in hypertensive patients. Hypertension. 1995;25: 651-659.
34. van der Meer IM, de Maat MP, Bots ML, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2002;22: 838-842.
35. DeSouza CA, Dengel DR, Macko RF, et al. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens. 1997;10: 1335-1341.
36. Kuroda YT, Komamura K, Tatsumi R, et al. Vascular cell adhesion molecule-1 as a biochemical marker of left ventricular mass in the patients with hypertension. Am J Hypertens. 2001;14: 868-872.
37. Malmqvist K, Wallén HN, Held C, et al. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens. 2002;20: 1563-1569.
38. Luc G, Arveiler D, Evans A, et al. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis. 2003;170: 169-176.
39. Glowinska-Olszewska B, Tolwinska J, Luczynski W, et al. Cardiovascular risk in nonobese hypertensive adolescents: a study based on plasma biomarkers and ultrasonographic assessment of early atherosclerosis. J Hum Hypertens. 2013;27: 191-196.
40. Mörtsell D, Malmqvist K, Held C, et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med. 2007;261: 472-479.
41. Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensinconverting enzyme inhibitor "beyond blood pressure lowering": beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23: 551-556.
42. Schillaci G, Parati G, Pirro M, et al. Ambulatory arterial stiffness index is not a specific marker of reduced arterial compliance. Hypertension. 2007; 49: 986-991.
43. Matsui Y, O'Rourke MF, Ishikawa J, et al. Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study. Am J Hypertens. 2012;25: 862-868.
44. Ekholm M, Kahan T, Jörneskog G, et al. Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. Thromb Res. 2009;124: 110-115.
45. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002;105: 457-461.
46. Rosei EA, Rizzoni D, Muiesan ML, et al CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens. 2005;23: 435-444.
47. Serg M, Kampus P, Kals J, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012;72: 427-432.
48. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44: 362-368.
49. Cesari M, Kritchevsky SB, Atkinson HH, et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009;157: 334.e1-334.e8.